Comparative Effects of Pilates Breathing and Pursed Lip Breathing on Chest Expension and Peak Expiratory Flow Rate in Patients With Chronic Obstructive Lung Disease
1 other identifier
interventional
46
1 country
1
Brief Summary
Chronic Obstructive Pulmonary Disease is a particular type of irreversible disease that may damage or obstruct airways and make it difficult to breath. This respiratiry condition may lead to shallow breathing. Breathing exercisers help to manage hyperventilation often seen in COPD patients. To handle respiratory complications patients are advised to practice breathing techniques along with pharmacological management
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Sep 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 10, 2025
CompletedStudy Start
First participant enrolled
September 15, 2025
CompletedFirst Posted
Study publicly available on registry
September 17, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2026
CompletedOctober 7, 2025
September 1, 2025
4 months
September 10, 2025
October 2, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Chest Expansion
Evaluation will be done using inch tape (inches) for Chest Expansion
03 weeks
Peak expiratory flow rate
Evaluation will be done by using Peak flow meter
03 weeks
Dyspnea
Evaluation will be done by using Modified Medical Research Council Dyspnea Scale (mMRC)
03 weeks
Study Arms (2)
Group A
EXPERIMENTALPatients in this group will receive Pilates breathing techniques along with pharmacological management for total of 3 weeks. Two sessions per week will be supervised by physiotherapist and 5 days at home. A home diary will be provided in order to ensure and follow-up of the participants are performing breathing exercises at home.
Group B
EXPERIMENTALPatients in this group will receive Pursed-lip breathing along with pharmacological management for 3 weeks. Two sessions per weeek will be supervised by physiotherapist and 5 days at home. A home diary will be provided in order to ensure and follow-up of the participants that they are performing breathing exercises at home.
Interventions
Patients in this group will receive pilates breathing technique along with pharmacological management. A total 3 weeks protocol will be followed in which 2 seesions per week will be supervised by physiotherapist and 5 days at home. Pilates breathing will be performed in sitting or supine position. The patient will place a hand over the Lower Posterior rib Cage and inhale through the nose. While breathing they will actively contract the Transverse Abdominis (TrA) as if preparing for punch or holding in urine and engaging the pelvic floor muscles.
Patient in this group will receive pursed-lip breathing along with pharmacological management. A total 3 weeks protocol will be followed in which 2 sessions per week will be supervised by physiotherapist and 5 days at home. The patient will sit comfortably with straight back and relaxed shoulders. They will inhale slowly through the nose, with a deep relaxed breath, and then exhale slowly through the pursed lips, as if blowing out a candle. The exhalation should take 2-3 times longer than inhalation. This breathing cycle will be repeated with a focus on slow and relaxed breathing. Pharmacological management: Patient will receive medications as per prescribed by pulmonologist
Eligibility Criteria
You may qualify if:
- Age between 40-64 years
- Both genders (male and female)
- Grade 1-3 on mMRC scale of dyspnea
- COPD mild stage according to global initiative for chronic obstructive lung disease (GOLD) classification; Mild = FEV1 greater than or equal to 80% predicted
You may not qualify if:
- Moderate, severe and very severe stage of COPD according to GOLD classification
- Patients having acute exerbation of COPD
- Patients diagnosed with acute infection
- Patients unable to follow command and instructions
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Foundation University College of Physical Therapy, Islamabad, 44000
Rawalpindi, 46000, Pakistan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 10, 2025
First Posted
September 17, 2025
Study Start
September 15, 2025
Primary Completion
January 1, 2026
Study Completion
February 1, 2026
Last Updated
October 7, 2025
Record last verified: 2025-09